Navigation Links
Sinovac Reports Unaudited Full Year 2008 and Fourth Quarter Financial Results
Date:4/9/2009

r 31, 2008 were $17.5 million, compared to $12.0 million in the same period of 2007. SG&A expenses as a percentage of sales represented 37.6% in the 2008 period, compared to 35.7% in the same period of last year.

Net expenditures on research and development expenses for the twelve months ended December 31, 2008 were $2.8 million, compared to $965,000 in the same period of 2007. The increase in R&D expense for 2008 was partly attributable to the expenses for the development of its vaccines against avian flu, EV 71 and animal rabies.

Operating income was $15.6 million for the twelve months ended December 31, 2008, compared to $13.5 million in the same period of 2007. The year-over-year increase in operating income reflected increased sales of hepatitis A and hepatitis A&B vaccine in 2008.

Net income for the twelve months ended December 31, 2008 included $702,000 of interest and financing expenses, $3.0 million of income taxes expense, $291,000 of interest and other income and $4.2 million of minority interest. Net income for the same period of 2007 included $478,000 of interest and financing expenses, $2.0 million of income taxes, $191,000 of interest and other income and $3.6 million of minority interest. Net income for the twelve months ended December 31, 2008 was $8.0 million, or $0.19 per diluted share, compared to $7.7 million, or $0.19 per diluted share, in the same period of 2007.

In March 2009, Sinovac Beijing was granted High and New Technology Enterprises (HNTE) status by the Chinese government. HNTEs are entitled to the preferential income tax rate of 15%, compared to the unified income tax rate of 25%, retroactively to January 1, 2008. Sinovac Beijing will benefit from the lower tax rate for a three-year period, covering 2008, 2009 and 2010.

Retroactively applying the HNTE tax rate of 15% for the full year ended December 31, 2008 resulted in a $2.1
'/>"/>

SOURCE Sinovac Biotech Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. Sinovac Announces Postponement of Annual General Meeting
2. Sinovac Requests Extension for Annual Shareholders Meeting
3. Sinovac Reports Top-Line Preliminary Phase II Results of Pandemic Influenza (H5N1) Whole Viron Vaccine
4. Sinovac Closes $9.75 Million Private Placement
5. Sinovac Biotech Ltd. Schedules 2007 Annual Meeting of Shareholders
6. Sinovac Announces Adjournment of Annual General Meeting
7. Sinovac to Host Conference Call to Report Fourth Quarter and Full Year 2007 Financial Results
8. Sinovac Reports Fourth Quarter and Full Year 2007 Financial Results
9. Sinovac Biotech Holds Annual General Meeting
10. Sinovac to Present at the Brean Murray, Carret & Co. All-Cap All-China Conference and the Roth China Discovery Tour 2008
11. Sinovac Receives RMB 20 Million Purchase Order for Healive from Chinas Ministry of Health to Vaccinate Earthquake Victims
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Village, Calif. (PRWEB) January 15, 2014 ... treatment and management through the genomic analysis of tumor ... offer Therapy Finder™, a web-based cancer decision support application ... reporting option with Cynvenio’s ClearID™ genomic test, Therapy Finder ...
(Date:1/15/2014)... Toronto, Canada (PRWEB) January 15, 2014 ... perspectives on nonclinical and clinical safety assessment in biosimilars. ... a path for biosimilar drug development, however the complex ... regards to quality, safety and efficacy extremely challenging. Based ...
(Date:1/15/2014)... 15, 2014 Two champions of science, ... sponsorship of an annual competition for middle and high ... to, innovative STEM study. The competition presents students with ... of Engineering Aptitude, Mathematics, and Sciences is a ...
(Date:1/15/2014)... 2013 was a banner year of continued ... saw continued independent research led by the team at ... $1 million grant from the Susanne Marcus Collins Foundation, ... peer reviewed journal, Amy Grant highlighted Brainwave Optimization® in ...
Breaking Biology Technology:Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 2Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 3Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 2Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 3Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 4Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 5Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 2Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 3
... Inc. (NTI(R)) (Nasdaq: NTII ), today announced ... GmbH (Merz) for sales,by Merz and its marketing ... disease for the quarter ended September 30,2007. Under ... payments on sales of Memantine by Merz and ...
... improved but still flawed government-wide plan for nanotechnology ... system. Federally-funded studies essential to managing possible ... by a top-down strategy tied to projected commercialization, ... decision-making process. , The National Nanotechnology ...
... collaboration between researchers at the National Institute of Standards ... Kentucky potentially offers a low-cost way to mass produce ... for a wide range of applications including flexible displays, ... field diagnostics. , In a paper posted this week,* ...
Cached Biology Technology:Neurobiological Technologies Reports $2.1 Million Quarterly Payment for Sales of Memantine 2Federal nanotech risk research plan still comes up short 2Directed self-ordering of organic molecules for electronic devices 2
(Date:7/9/2014)... common frog is one of the amphibians with the ... in permanent areas of water where it comes into ... its larvae. Research carried out by the Spaniard Germn ... the larvae of these frogs have developed a defensive ... tails and larger bodies if they co-exist with the ...
(Date:7/9/2014)... measurement results accrue. To completely and systematically archive ... In fact, researchers in the life sciences spend ... to an online survey of 70 people working ... for Applied Information Technology FIT in Sankt Augustin. ... no centralized or structured approach to data collection ...
(Date:7/9/2014)... inhibitors and N-methyl-D-aspartate receptor antagonists can alleviate ... to affect irreversible cognitive dysfunction and effectively ... Amyloid beta peptide (Aβ) vaccines reduced and ... (AD) transgenic mouse model, and significantly improved ... and his team, First Affiliated Hospital of ...
Breaking Biology News(10 mins):Frogs have developed rapid defences against the red swamp crayfish 2Frogs have developed rapid defences against the red swamp crayfish 3Managing the data jungle 2Managing the data jungle 3
... of vertebrate species, but while groups such as mammals, birds ... decades, knowledge about relationships among many types of fishes was ... of scientists led by Richard Broughton, associate professor of biology ... of Oklahoma, published two studies that dramatically increase understanding of ...
... proportion of black carbon created during combustion will remain in ... burying black carbon in the ground in order to restrain ... a part of black carbon will dissolve from soil to ... to the ocean was estimated in a research article published ...
... the University of Birmingham, BGI and its open-access ... the UK,s Natural Environment Research Council (NERC) to ... large-scale environmental metabolomics data. Metabolomics involves the ... living organisms and can provide an indication of ...
Cached Biology News:Something's fishy in the tree of life 2'Black carbon' flowing from soil to oceans 2Collaboration to establish new computational resources for metabolomics 2
RABBIT ANTI HUMAN TRRAP (CT) Immunogen: Recombinant C-terminal kinase-related domain of human TRRAP....
RABBIT ANTI HUMAN CHYMOTRYPSIN...
MSE ANTI CAN. CD3:FITC/RAT ANTI CD4:RPE...
MOUSE ANTI POLY (ADP-RIBOSE) Immunogen: Purified poly (ADP-ribose) polymer, 10-50 unit chain length...
Biology Products: